Contents:

EXECUTIVE SUMMARY Scope Datamonitor insight into the immunotherapies market Market Summary IMMUNOTHERAPY MARKET DEFINITION Market definition Therapy classes covered Disease indications Epidemiology overview Immunotherapy drug class definitions Cytokines Monoclonal antibodies Therapeutic vaccines Definition of gold standard drugs/classes Class comparisons Comparisons within the immunotherapies class MARKET ANALYSIS Global market analysis Global immunotherapies market analysis by drug class Overview of the current cancer immunotherapies market Key trends in the immunotherapies market Class Overview: Cytokines Overview of the global cytokines market Key trends in the global cytokines market Comparison of key cytokine brands Intron A (interferon alpha) Sumiferon Proleukin (aldesleukin, interleukin-2) Class overview: Monoclonal antibodies Key trends in the monoclonal antibodies cancer therapeutic market Comparison of key monoclonal antibody brands Rituxan/MabThera (rituximab) Herceptin (trastuzumab) Panorex (edrecolomab) Campath (alemtuzumab) Mylotarg (gemtuzumab) Class overview: Therapeutic vaccines Melacine (theraccine) M-Vax OncoVax Country analysis Significant countries in the global immunotherapies market Overview of the global immunotherapies market Additional market-specific factors affecting immunotherapies LATE-STAGE PIPELINE DRUG ANALYSIS Introduction Cytokines in late-stage development Pegylated interferons Monoclonal antibodies Vaccine Therapies COMPARATIVE ANALYSIS Comparisons of drugs in development Comparison of traditional therapy with immunotherapies Cytokines versus traditional chemotherapy – is there enough of a difference? Pegylated cytokines - how much of an impact will convenience have? Monoclonal antibodies – able to mop up after other modalities? Non-Hodgkin’s lymphoma – a critical proving ground? Conjugated versus unconjugated: is the double-punch worth higher developmental costs? Therapeutic vaccines – too new to compare? Melanoma and colorectal vaccines – surviving the jostling in too crowded a market Conclusion LIFECYCLE MANAGEMENT Global immunotherapy class lifecycle Reformulations in the immunotherapies class Lifecycle management case studies Case study 1: Extensions of product competitiveness through launch of pegylated interferons: Schering’s PegIntron. Case study 2: Extensions of product competitiveness through launch of conjugated monoclonal antibodies: Genentech’s Zevalin. Case study 3: Life-cycle extension through broader indications: Erbitux THE FUTURE DECODED Market forecasting methodology Immunotherapies class market growth Individual drug growth Trends in the immunotherapies market to 2008 Market forecast Drug class forecast Product forecasts Alternative forecast scenarios Appendix Datamonitor's Oncology Business Unit Table of tables Table of figures Sales data research methodology Introduction Hypothesis formulation Hypothesis testing Data verification with key contacts Quality control Quantification of data reliability Exchange rates References